Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Time To Strike On Regenerative Medicine/Stem Cell Companies?

Executive Summary

As the hype that accompanied the revelation of regenerative medicine recedes, biotechs that survived the transition from science experiment to market-focused company have now settled into the same realities that face the rest of the industry in terms of making the case for reimbursement and preparing for regulatory scrutiny, not to mention the exit question.

You may also be interested in...

France's Cellectis To Acquire Cellartis To Produce A Leader In Stem Cell Technologies

The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.

Cell-Therapy Deals A "Strategic Priority" For Shire

Shire seeks to build on its May 2011 acquisition of Advanced BioHealing with further cell-therapy deals.

Advanced BioHealing To Bring Regeneration To Shire

The evening before Advanced BioHealing Inc. was set to debut on the New York Stock Exchange on May 18, it announced that Shire PLC has agreed to buy it for $750 million.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts